These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6056043)

  • 1. Irreversible enzyme inhibitors. 108. 6-(p-chloroacetylanilinomethyl)-5-(p-chlorophenyl)-2,4-diaminopyrimidine, an active-site-directed irreversible inhibitor of dihydrofolic reductase.
    Baker BR; Huang PC; Pogolotti AL
    J Med Chem; 1967 Nov; 10(6):1134-8. PubMed ID: 6056043
    [No Abstract]   [Full Text] [Related]  

  • 2. Irrevesible enzyme inhibitors. CLI. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 5-(p-aminophenylbutyl)-2,4-diaminopyrimidines with a terminal sulfonyl fluoride.
    Baker BR; Meyer RB
    J Med Chem; 1969 Mar; 12(2):224-7. PubMed ID: 5254099
    [No Abstract]   [Full Text] [Related]  

  • 3. Irreversible enzyme inhibitors. CV. Differential irreversible inhibition of vertebrate dihydrofolic reductases by derivatives of 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazines substituted with a terminal sulfonyl fluoride.
    Baker BR; Lourens GJ
    J Med Chem; 1967 Nov; 10(6):1113-22. PubMed ID: 6056040
    [No Abstract]   [Full Text] [Related]  

  • 4. Irreversible enzyme inhibitors. 158. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamidomethyl)phenoxymethyl]pyrimidine. II.
    Baker BR; Vermuelen NM
    J Med Chem; 1969 Jul; 12(4):684-8. PubMed ID: 5793162
    [No Abstract]   [Full Text] [Related]  

  • 5. Irreversible enzyme inhibitors. CXX. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-substituted 2,4-diamino-5-phenylpyrimidines with tissue specificity.
    Baker BR; Huang PC
    J Med Chem; 1968 May; 11(3):495-500. PubMed ID: 5241409
    [No Abstract]   [Full Text] [Related]  

  • 6. Irreversible enzyme inhibitors. CXIX. Active-site-directed irreversible inhibitors of dihydrofolic reductase with tissue specificity derived from 2,4,6-triaminopyrimidine with a terminal sulfonyl fluoride at the 5 position.
    Baker BR; Meyer RB
    J Med Chem; 1968 May; 11(3):489-94. PubMed ID: 5241408
    [No Abstract]   [Full Text] [Related]  

  • 7. Irreversible enzyme inhibitors. 143. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 5-(p-aminophenoxypropyl)-2,4-diamino-6-methylpyrimidine with a terminal sulfonyl fluoride.
    Baker BR; Meyer RB
    J Med Chem; 1969 Jan; 12(1):108-11. PubMed ID: 5763004
    [No Abstract]   [Full Text] [Related]  

  • 8. Irreversible enzyme inhibitors. 138. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-(p-aminomethylphenethyl)-- 2,4-diamino-5-(3,4-dichlorophenyl)pyrimidine with a terminal sulfonyl fluoride.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):89-91. PubMed ID: 5763048
    [No Abstract]   [Full Text] [Related]  

  • 9. Irreversible enzyme inhibitors. CXXXVI. 2,4-Diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamido)phenoxymethyl]pyrimidine, an active-site-directed irreversible inhibitor of dihydrofolic reductase. Effect of structure on isozyme specificity.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):82-5. PubMed ID: 5763046
    [No Abstract]   [Full Text] [Related]  

  • 10. Irreversible enzyme inhibitors. CXLII. Further studies on active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 5-(p-Aminophenoxypropyl)-2,4,6-triaminopyrimidine bearing a terminal sulfonyl fluoride.
    Baker BR; Meyer RB
    J Med Chem; 1969 Jan; 12(1):104-7. PubMed ID: 5763003
    [No Abstract]   [Full Text] [Related]  

  • 11. Irreversible enzyme inhibitors. CXVI. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-substituted 2,4-diamino-5-phenylpyrimidines. 3.
    Baker BR; Huang PC; Meyer RB
    J Med Chem; 1968 May; 11(3):475-82. PubMed ID: 5241405
    [No Abstract]   [Full Text] [Related]  

  • 12. Irreversible enzyme inhibitors. CXXXVII. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-(p-aminomethylphenoxymethyl)-2,4-diamino-5-(3,4-dichlorophenyl)pyrimidine bearing a terminal sulfonyl fluoride.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):86-8. PubMed ID: 5763047
    [No Abstract]   [Full Text] [Related]  

  • 13. Irreversible enzyme inhibitors. CLVII. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamidomethyl)phenoxymethyl]pyrimidine. I.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jul; 12(4):680-4. PubMed ID: 5793161
    [No Abstract]   [Full Text] [Related]  

  • 14. Irreversible enzyme inhibitors. CLVII. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosultonyl-benzamidomethyl) phenozymethyl]pyrimidine. I.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jul; 12(4):680-4. PubMed ID: 5822623
    [No Abstract]   [Full Text] [Related]  

  • 15. Irreversible enzyme inhibitors. CXVII. Hydrophobic bonding to dihydrofolic reductase. XI. Comparison of the enzyme from Walker 256, rat liver, and L1210 mouse leukemia.
    Baker BR
    J Med Chem; 1968 May; 11(3):483-6. PubMed ID: 5241406
    [No Abstract]   [Full Text] [Related]  

  • 16. Irreversible enzyme inhibitors. CXXXVI. 2,4-Diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenz amido) phenoxymethyl] pyrimidine, an active-site-directed irreverisible inhibitor of dihydrofolic reductase. Effect of structure on isozyme specificity.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):82-5. PubMed ID: 5777842
    [No Abstract]   [Full Text] [Related]  

  • 17. Irreversible enzyme inhibitors. CXXXV. Effect of ring substitution on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(p-fluorosulfonyl-phenylureido)phenoxymethyl]pyrimidine.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):79-81. PubMed ID: 5763045
    [No Abstract]   [Full Text] [Related]  

  • 18. Irreversible enzyme inhibitors. CLIV. Some factors in cell wall transport of active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 5-substituted 2,4-diaminopyrimidines.
    Baker BR; Meyer RB
    J Med Chem; 1969 Jul; 12(4):668-71. PubMed ID: 5793159
    [No Abstract]   [Full Text] [Related]  

  • 19. Irreversible enzyme inhibitors. CXXXIV. Effect of ring substitution on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonyl-phenylureido)phenoxymethyl]pyrimidine.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):74-8. PubMed ID: 5763044
    [No Abstract]   [Full Text] [Related]  

  • 20. Irreversible enzyme inhibitors. CXII. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine substituted with a terminal sulfonyl fluoride. II.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):38-41. PubMed ID: 5237173
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.